


IN THE SPECIFICATION:

Please amend the specification passage at page 3, lines 16-20 as follows:


According to a further aspect of the present invention there is provided a compound of formula (IC):



wherein:

Please amend the specification passage at page 4, line 22 through page 5, line 20 as follows:

According to a further aspect of the present invention there is provided a compound of formula (IE):



wherein:

R^1 is hydrogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, a heterocyclyl or heterocyclyl C_{1-3} alkyl; wherein R^1 may be

optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

p is 1-2; wherein the values of R^2 may be the same or different;

R^3 is hydrogen, halo or cyano;

R^4 is C_{1-4} alkyl;

~~R^5 is C_{1-6} alkyl or C_{2-6} alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;~~

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that said compound is not

4-(1,2-dimethylimidazol-5-yl)-2-[2-methoxy-4-(*N*-methylsulphamoyl)-5-methylanilino]-pyrimidine.

Please amend the paragraph at page 23, lines 6-9, as follows:

As stated hereinbefore the compounds defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the CDK inhibitory activity of the compound. These properties may be assessed, for example, using the procedures set out in WO 02/04429 (corresponding to US Patent 6,908,920).